Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

sion-free survival (PFS), and overall survival (OS), and with the exception of OS, analyses were based on IRF data. Response-evaluable patients were defined as patients with measurable disease, as determined by the IRF, which met the resistance criteria for anthracyclines, taxanes, and capecitabine. Results of the 113 response-evaluable patients were assessed by the IRF, as well as independently by investigators at the study site, and showed:

    -- Objective response rate was achieved in 11.5% of patients as determined

       by the IRF and 18.6% as determined by the investigators.

    -- Median duration of response of 5.7 months.

    -- Median time to response of 6.1 weeks.

    -- Median progression-free survival of 3.1 months.

    -- Median overall survival of 8.6 months.

Overall treatment-related non-hematological adverse events greater than or equal to 20% included: peripheral sensory neuropathy 60% (Grade 3/4: 14%); fatigue/asthenia 50% (Grade 3/4: 14%); myalgia/arthralgia 49% (Grade 3/4: 8%); alopecia 48% (Grade 3/4: 0%); nausea 42% (Grade 3/4: 2%); stomatitis/mucositis 29% (Grade 3/4: 7%); vomiting 29% (Grade 3/4: 1%); diarrhea 22% (Grade 3/4: 1%); and musculoskeletal pain 20% (Grade 3/4: 3%). Treatment-related hematological adverse events greater than or equal to 20% included: leukopenia 90% (Grade 3/4: 49%); anemia 84% (Grade 3/4: 8%); neutropenia 79% (Grade 3/4: 54%); and thrombocytopenia 44% (Grade 3/4: 8%).

About Ixabepilone

Ixabepilone is an investigational compound, a semisynthetic analog of epothilone B, designed to inhibit or prevent the growth or development of cancer cells. Epothilones are a potential new class of antineoplastic (or chemotherapy) agents. For information on ixabepilone clinical trials, log on to www.clinicaltrials.gov.

On June 19, 2007 the company announced that the U.S. Food and Drug Administration has accepted, for filing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/18/2014)... GREENVILLE, S.C. , Sept. 18, 2014 /PRNewswire/ ... a $1.975 million Small Business Innovation Research (SBIR) ... (NCI), one of the 27 institutes and centers ... Over the course of the two year award, ... to address two issues at the forefront of ...
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, ... was recognized as the Disruptive Innovator of ... ePharmaONE cloud-based eClinical platform. This solution includes ... trial master file (eTMF), a remote monitoring ... ePharmaSolutions, ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... S.C. , Sept. 18, 2014   3D Systems ... of the Simbionix RobotiX Mentor™ , a new robotic ... for the first time at the ERUS exhibition in ... 19 (booth #7). Robotic-assisted minimally invasive surgery represents ... demand means the needs for training for robotic surgery has ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... , KALAMAZOO, Mich., Dec. 31 Stryker ... of its previously announced acquisition of Ascent Healthcare Solutions, the ... in the U.S. , "The acquisition of Ascent Healthcare Solutions ... of the most impactful programs in use at hospitals, allowing ...
... , Ruling Opens Door to Physician Assisted ... Montana Supreme Court ruled that state law does not contain ... drugs to patients. This decision endangers the lives of the ... people,s lives, the law needs to draw a clear distinction ...
Cached Medicine Technology:Stryker Completes Acquisition of Ascent Healthcare Solutions 2Montana Supreme Court Decision Endangers Most Vulnerable Citizens 2
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Research conducted by a team of ... has documented improved survival in patients with cancerous ... tumors along with stereotactic radiosurgery. , The study was ... (American Society for Radiation Oncology) this week in San ... radiation beams to treat tumors in the brain, delivering ...
(Date:9/18/2014)... and London. (PRWEB) September 18, 2014 ... Computer Aided Engineering software, today announced its new partnership ... be utilizing the CD-adapco simulation tool, STAR-CCM+® in the ... just announced its participation in the 35th America’s Cup ... 35th edition of the America’s Cup is sustainability, the ...
Breaking Medicine News(10 mins):Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
... studying rare genetic disorders have uncovered insights into ... when cells divide. Focusing on the cohesin complex, ... encircles chromosome pairs, scientists have discovered mutations that ... diseases called cohesinopathies. "We are learning more ...
... Israel; Seoul, South Korea, May 29, 2012 -- The ... enabled an Israeli-South Korean scientific team to conduct a genetic ... B virus (HBV) genotype C2 sequence common in Southeast Asia. ... be used as a model to study the evolution of ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
... battle: Long after a cancer has been beaten into remission, it ... is unclear. New research led by Weizmann Institute scientists shows that, ... cancer recurrence is in a set of cells that do not ... survive chemotherapy. The findings, which appeared today in the journal ...
... not healthy. However, new research from the University of Copenhagen ... vitamin is not good either. The study is based on ... published in the reputed scientific Journal of Clinical Endocrinology ... calcium reach our bones, thus lessening the risk from falls ...
... , MONDAY, May 28 (HealthDay News) -- Women who work ... increasing their risk for breast cancer, Danish researchers find. ... women who describe themselves as "morning" people rather than "evening" ... of women in modern societies have night shift work," said ...
Cached Medicine News:Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: